Reply to Comment on: Fungal keratitis: The Aravind Experience
Sir, We would like to thank the reviewers for their interest in our publication. [1] Investigators in our department along with our collaborators conducted a randomized trial comparing the various concentrations of topical chlorhexidine (0.05%, 0.1%, and 0.2%) with 5% natamycin for fungal keratitis at our institution in 1997 and concluded that, the nonsevere fungal ulcers with no prior antifungal treatment, when treated with 0.2% chlorhexidine had a favorable outcome at 5 days from the initiation of the treatment compared to 5% natamycin. [2] However, comparison of the long-term outcome of nonsevere fungal ulcers was not statistically significant among the four groups. There was no difference in the outcomes of severe fungal ulcers. The study was limited by small sample size with 8 ulcers in chlorhexidine 0.2% group compared to 16 ulcers in natamycin group. Chlorhexidine is a nonspecific antiseptic which is not commercially available in our region and has to be formulated under strict aseptic precautions. The shelf life of chlorhexidine is <2 weeks. Hence, in our clinical practice, we reserve chlorhexidine 0.2% for corneal ulcers caused by acanthamoeba and we do not use it in fungal keratitis.
Mycotic ulcer treatment trial 2 (MUTT 2) evaluated the efficacy of oral voriconazole as an adjunct to topical antifungals in severe fungal keratitis [3] and concluded that oral voriconazole does not give added benefit in such a scenario. In this trial, topical natamycin was added to topical voriconazole in both the arms after analyzing the results of MUTT 1, which concluded that topical voriconazole should not be used as a monotherapy. [4] This addition of topical natamycin happened after the enrollment of 39 patients of the total sample size of 240 patients. The less number of patients receiving only topical voriconazole precludes any meaningful comparison to establish the superiority of using both natamycin and voriconazole. However, in our clinical practice, we do add topical voriconazole to topical natamycin in large, recalcitrant, and deep ulcers.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
Venkatesh N Prajna, Lalitha Prajna 1 , Srinivasan Muthiah
Letters to the Editor
Comment on: Systemic analysis of ocular trauma by a new proposed ocular trauma classification
Sir, We read your article with keen interest and congratulate you for the efforts taken to create a comprehensive classification system for ocular trauma. [1] It was the need of the hour considering the deficiencies of the previous systems. We also understand that no classification system can completely encompass the whole spectrum of ophthalmic injuries as most of them are mixed.
As we read the article, we came across a few points which we would like you to clarify. We would like to know if intramural foreign body can be classified in destructive globe injuries since the thickness through which the foreign body penetrates the ocular coats is not specified.
Further, one-third full-thickness laceration has been classified as a destructive injury. We believe that a lamellar laceration (closed globe type) cannot be differentiated from a one-third full-thickness laceration (destructive globe type). The classification system previously published by the authors is much realistic in classifying the destructive injuries with full thickness laceration and one-third globe circumference. [2] We would also like to know if classifying into a new group of mixed injuries which include global and adnexal injuries as was seen previously would help make the classification system more comprehensive. We firmly believe that it is much more imperative to incorporate and comprehend collectively the foreign body injuries within the classification of ocular trauma. [2] Financial support and sponsorship Nil.
Conflicts of interest
There are no conflicts of interest. 
Preet Kanwar Singh Sodhi, Aditya Verma

